# Novel Triple-dose Tuberculosis Retreatment Regimen

> **NCT04260477** · PHASE3 · RECRUITING · sponsor: **Institute of Tropical Medicine, Belgium** · enrollment: 370 (estimated)

## Conditions studied

- Multidrug-resistant Tuberculosis
- Pulmonary Tuberculosis
- Tuberculosis
- Resistance to Tuberculostatic Drugs

## Interventions

- **DRUG:** 6EH³R³Z
- **DRUG:** 6EHRZ

## Key facts

- **NCT ID:** NCT04260477
- **Lead sponsor:** Institute of Tropical Medicine, Belgium
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2025-06
- **Final completion:** 2025-09
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04260477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04260477, "Novel Triple-dose Tuberculosis Retreatment Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04260477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*